These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23665160)

  • 81. Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease.
    Tayebi N; Cushner S; Sidransky E
    Am J Hum Genet; 1996 Sep; 59(3):740-1. PubMed ID: 8751878
    [No Abstract]   [Full Text] [Related]  

  • 82. A new glucocerebrosidase-gene missense mutation responsible for neuronopathic Gaucher disease in Japanese patients.
    Kawame H; Eto Y
    Am J Hum Genet; 1991 Dec; 49(6):1378-80. PubMed ID: 1840477
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient.
    Choy FY; Humphries ML; Ben-Yoseph Y
    Am J Med Genet; 1998 Jun; 78(1):92-3. PubMed ID: 9637431
    [No Abstract]   [Full Text] [Related]  

  • 84. Assessment of cellular cobalamin metabolism in Gaucher disease.
    Basgalupp SP; Siebert M; Ferreira C; Behringer S; Spiekerkoetter U; Hannibal L; Schwartz IVD
    BMC Med Genet; 2020 Jan; 21(1):12. PubMed ID: 31931749
    [TBL] [Abstract][Full Text] [Related]  

  • 85. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.
    Sardi SP; Clarke J; Kinnecom C; Tamsett TJ; Li L; Stanek LM; Passini MA; Grabowski GA; Schlossmacher MG; Sidman RL; Cheng SH; Shihabuddin LS
    Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12101-6. PubMed ID: 21730160
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable.
    Berger J; Stirnemann J; Bourgne C; Pereira B; Pigeon P; Heraoui D; Froissart R; Rapatel C; Rose C; Belmatoug N; Berger MG
    Br J Haematol; 2012 Apr; 157(2):274-7. PubMed ID: 22224474
    [No Abstract]   [Full Text] [Related]  

  • 87. Novel mutation, L371V, causing multigenerational Gaucher disease in a Lebanese family.
    Shamseddine A; Taher A; Fakhani S; Zhang M; Scott CR; Habbal MZ
    Am J Med Genet A; 2004 Mar; 125A(3):257-60. PubMed ID: 14994233
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.
    Schiffer V; Santiago-Mujika E; Flunkert S; Schmidt S; Farcher M; Loeffler T; Schilcher I; Posch M; Neddens J; Sun Y; Kehr J; Hutter-Paier B
    PLoS One; 2020; 15(1):e0227077. PubMed ID: 31929594
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades.
    Hopf S; Pfeiffer N; Liesenfeld M; Mengel KE; Hennermann JB; Schmidtmann I; Pitz S
    Orphanet J Rare Dis; 2019 Nov; 14(1):257. PubMed ID: 31727115
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Progression of retinal changes in Gaucher disease: a case report.
    Coussa RG; Roos JC; Aroichane M; Miron MC; Ospina LH
    Eye (Lond); 2013 Nov; 27(11):1331-3. PubMed ID: 23970031
    [No Abstract]   [Full Text] [Related]  

  • 91. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
    Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
    Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases.
    Liou B; Haffey WD; Greis KD; Grabowski GA
    J Biol Chem; 2014 Oct; 289(43):30063-74. PubMed ID: 25202012
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
    Tayebi N; Walker J; Stubblefield B; Orvisky E; LaMarca ME; Wong K; Rosenbaum H; Schiffmann R; Bembi B; Sidransky E
    Mol Genet Metab; 2003 Jun; 79(2):104-9. PubMed ID: 12809640
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene.
    Sidransky E; Sherer DM; Ginns EI
    Pediatr Res; 1992 Oct; 32(4):494-8. PubMed ID: 1437405
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Predicting parkinsonism: new opportunities from Gaucher disease.
    Lopez G; Sidransky E
    Mol Genet Metab; 2013 Jul; 109(3):235-6. PubMed ID: 23665160
    [No Abstract]   [Full Text] [Related]  

  • 96. Retinal thinning in Gaucher disease patients and carriers: results of a pilot study.
    McNeill A; Roberti G; Lascaratos G; Hughes D; Mehta A; Garway-Heath DF; Schapira AH
    Mol Genet Metab; 2013 Jun; 109(2):221-3. PubMed ID: 23639447
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Novel G377S (c.1246G>T) mutation associated with Gaucher disease type 1.
    Zhou Y; Kraemer RR; Peker D; Wakefield DN; de Idiaquez Bakula DA
    Am J Hematol; 2013 Oct; 88(10):922-3. PubMed ID: 23828321
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.